Skip to content
SecularTimes
  • HOME
  • WORLD
  • POLITICS
  • ENTERTAINMENT
  • AUTOMOBILE
  • BUSINESS
  • TECHNOLOGY
  • LIFESTYLE
  • HEALTH
  • MORE
    • COVID-19
    • COMICS
    • SPORTS
    • SCIENCE
    • TRAVEL

Eli Lilly and Co

Radiopharmaceuticals race heats up as drugmakers chase Novartis

by Tudur Aled
Radiopharmaceuticals race heats up as drugmakers chase Novartis

Drugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough.  Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical companies have spent some $10 …

Read more

We ranked Q2 earnings from 30 portfolio stocks from great to ugly

by Joseph Addison
We ranked Q2 earnings from 30 portfolio stocks from great to ugly

It was a solid quarter for the companies in our stock portfolio, with the bulk of our names reporting what we felt were good-to-great earnings reports. Continued economic growth on …

Read more

Top 5 stocks in a downbeat market since the August Monthly Meeting

by Joseph Addison
Top 5 stocks in a downbeat market since the August Monthly Meeting

It’s been a topsy-turvy stock market since the Club’s August Monthly Meeting. The S & P 500 jumped 1.8% over the period, while the Dow Jones Industrial Average and Nasdaq …

Read more

Eli Lilly to boost output of weight loss, diabetes, Alzheimer’s drugs

by Sven Aggesen
Eli Lilly to boost output of weight loss, diabetes, Alzheimer’s drugs

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said …

Read more

57 million privately insured adults eligible for GLP-1s

by Sven Aggesen
57 million privately insured adults eligible for GLP-1s

Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images A version …

Read more

Jim Cramer says Apple (AAPL) is vulnerable ahead of iPhone 16 launch

by Joseph Addison
Jim Cramer says Apple (AAPL) is vulnerable ahead of iPhone 16 launch

Somewhere along the line we forgot how to value seven large companies. We knew they were better than almost all of the other companies out there. We knew that their …

Read more

Eli Lilly could become the first $1 trillion healthcare stock

by Sven Aggesen
Eli Lilly could become the first  trillion healthcare stock

A sign with the company logo outside the headquarters of Eli Lilly and Company in Indianapolis, Indiana, March 17, 2024. Scott Olson | Getty Images A version of this article …

Read more

Cramer debates buying AMD on weakness but needs to see oversold market

by Lucy Akhurst
Cramer debates buying AMD on weakness but needs to see oversold market

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. Wall Street started the troublesome …

Read more

We’re taking a nearly 300% profit on a hot drug stock

by Sven Aggesen
We’re taking a nearly 300% profit on a hot drug stock

Shortly after the opening bell, we’ll be selling 10 shares of Eli Lilly at roughly $958 each. Following Monday’s trade, Jim Cramer’s Charitable Trust will own 100 shares of LLY, …

Read more

Weight loss drugs cut Covid-19 deaths, study finds

by Joseph Addison
Weight loss drugs cut Covid-19 deaths, study finds

People taking the key component of blockbuster weight loss drugs Ozempic and Wegovy were less likely to die of Covid-19 or suffer adverse effects from the virus, researchers found in …

Read more

Older posts
Newer posts
← Previous Page1 Page2 Page3 … Page30 Next →

Recent Posts

  • The Role of Technology in Driving Innovation and Growth in UK Businesses
  • Steven Bartlett accused of amplifying dangerous health claims on his podcast | Podcasting
  • 2025 Volkswagen Taos Is Exactly What You Think It’s Going To Be
  • Canadians concerned country’s children are too soft, with no coping skills: survey
  • Apple MacBook Pro 16-inch (M4 Pro and M4 Max) review: still on top

Recent Comments

No comments to show.
  • ABOUT US
  • CONTACT US
  • PRIVACY POLICY
  • COOKIES POLICY
  • DISCLAIMER
  • TERMS OF USE
  • DMCA
© 2025 SecularTimes • Built with GeneratePress